SAN DIEGO, May 23, 2017 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a precision medicine biotechnology company, today
announced that its Chief Executive Officer, Bill Welch, will be presenting at the 7th Annual
LD Micro Invitational Conference June 7, 2017 at
11:30 AM PDT at the Luxe Sunset
Boulevard Hotel in Los Angeles,
CA. Management will also be available to meet with investors
during the conference.
The presentation will be webcast live at
http://wsw.com/webcast/ldmicro12/trov and can also be accessed
through the Trovagene website at www.trovagene.investorroom.com.
A replay of the presentation will be available and archived
for 90 days.
About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company
developing oncology therapeutics for improved cancer care by
leveraging its proprietary Precision Cancer Monitoring® (PCM)
technology in tumor genomics. Trovagene has broad
intellectual property and proprietary technology to measure
circulating tumor DNA (ctDNA) in urine and blood to identify and
quantify clinically actionable markers for predicting response to
cancer therapies. Trovagene offers its PCM technology at its
CLIA/CAP – accredited laboratory and plans to continue to
vertically integrate its PCM technology with precision cancer
therapeutics. For more information, please visit
www.trovagene.com.
Trovagene Contact
Vicki Kelemen
Sr. Director, Communications
858-952-7652
vkelemen@trovagene.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-7th-annual-ld-micro-invitational-conference-on-june-7-2017-in-los-angeles-300461742.html
SOURCE Trovagene, Inc.